ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1516

Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients

Tiphaine Lenfant1, Yuxuan Jin2, Elizabeth Kirchner3, Pauline Funchain2, Jung-Min Song2, Moshe Ornstein2, Laura Wood2, Donald Eicher2, Rula Hajj-Ali4, Leonard Calabrese2 and Cassandra Calabrese5, 1Institut Mutualiste Montsouris, Paris, France, 2Cleveland Clinic, Cleveland, OH, 3CCF, Cleveland, OH, 4Cleveland Clinic, Hunting Valley, OH, 5Cleveland Clinic Foundation, Cleveland Heights, OH

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Immune checkpoint inhibitor, immune-related adverse events

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Immunological Complications of Therapy Poster (1516–1529)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: To describe a single center cohort of rheumatic immune related adverse events (irAEs) observed in patients treated with checkpoint inhibitor therapy (ICI) and to identify potential risk factors for persistent rheumatic disease activity.

Methods: Patients referred to the Cleveland Clinic Department of Rheumatic and Immunologic Diseases for rheumatic irAE were retrospectively included and assessed via chart review (2015-2020). Persistent rheumatic irAE was defined as still requiring treatment for rheumatic irAE at last follow-up.

Results: A total of 112 patients (median age 60 years) were identified. The most common irAE clinical phenotypes included inflammatory arthritis (IA, n=46), sicca syndrome (n=21), and polymyalgia rheumatica (n=19). In the entire cohort ICI therapy was held temporarily for rheumatic irAE in 15 patients (13%) for toxicity and permanently discontinued in 26 (23%). At last follow-up, rheumatic irAE had resolved in 41 patients (37%), whereas 71 patients still required treatment of rheumatic irAE (median follow-up 15 months, range 5-30 months). Among therapies administered for irAE, glucocorticoids (GC) were most commonly prescribed (n=78, 70%), followed by hydroxychloroquine (16%), methotrexate (14%), and anti-IL-6 agents (11%). Patients with persistent rheumatic irAE activity more frequently received GC (p=0.018) and had IA (p=0.02) compared to patients that had resolution of irAE. In multivariate analysis, IA patients were at higher risk of persistent rheumatic irAE (OR 3.5 [1.3-10], p=0.014). The overall mortality rate was 27% (n=30). Risk factors for mortality included tumor progression (OR 15.3 [4-65], p< 0.001) and continued treatment with GC at the last follow-up (OR 5.8 [1.5-29], p=0.016). In a survival analysis, continued GC at the end of follow-up was significantly associated with mortality (HR 4.0 [1.3-12], p=0.0001).

Conclusion: In this single-center retrospective cohort of rheumatic irAEs patients, the presence of ICI-related IA was associated with persistent rheumatic disease activity.

Figure 1. Treatment of rheumatic irAEs Colchi: colchicine; GC: glucocorticoids; HCQ: hydroxychloroquine; Infl. A: inflammatory arthritis; IA: intra-articular; IL6-i: interleukin 6 inhibitors; MTX: methotrexate; RTX: rituximab;


Disclosures: T. Lenfant, None; Y. Jin, None; E. Kirchner, Sanofi, 12, Speaker's training, did not speak for company., Novartis, 1, Janssen, 1; P. Funchain, BMS, 5, Pfizer, 5; J. Song, None; M. Ornstein, Bristol Myers Squibb, 1, 2, 5, Merck, 2, Pfizer, 2, 5; L. Wood, Bristol Myers Squibb, 6, EMD Serono, 6, Merck, 6, Pfizer, 6; D. Eicher, None; R. Hajj-Ali, Novartis, 6, Rockpointe, INC., 6, Projects In Knowledge, 6, UpToDate, 9; L. Calabrese, Lilly, 2, BMS, 2, Genentech, 2; C. Calabrese, Sanofi-Regeneron, 2, 6.

To cite this abstract in AMA style:

Lenfant T, Jin Y, Kirchner E, Funchain P, Song J, Ornstein M, Wood L, Eicher D, Hajj-Ali R, Calabrese L, Calabrese C. Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/clinical-phenotypes-and-treatment-of-rheumatic-immune-related-adverse-events-from-checkpoint-inhibitors-a-retrospective-cohort-of-112-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-phenotypes-and-treatment-of-rheumatic-immune-related-adverse-events-from-checkpoint-inhibitors-a-retrospective-cohort-of-112-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology